2020
Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP. Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. International Journal Of Radiation Oncology • Biology • Physics 2020, 107: 334-343. PMID: 32084525, PMCID: PMC7276246, DOI: 10.1016/j.ijrobp.2020.01.051.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrain NeoplasmsBRCA1 ProteinBreast NeoplasmsFemaleHumansMiddle AgedPrognosisRetrospective StudiesSurvival AnalysisConceptsDiagnosis-specific prognostic factorsHuman epidermal receptor 2Prognostic factorsMedian survivalBreast-GPABrain metastasesBreast cancerCohort BCohort APrognostic indexReceptor 2Tumor subtypesBreast cancer brain metastasesKaplan-Meier survival estimatesCancer brain metastasesGraded Prognostic AssessmentKarnofsky performance statusLarge contemporary cohortLog-rank testFuture clinical trialsNew prognostic factorsGPA 0Extracranial metastasesPerformance statusBetter prognosis
2019
Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database
Mahal A, Butler S, Franco I, Muralidhar V, Larios D, Pike L, Zhao S, Sanford N, Dess R, Feng F, D’Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer 2019, 125: 3338-3346. PMID: 31251398, DOI: 10.1002/cncr.32332.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerPositive biopsy coresShort-term outcomesBiopsy coresProstate cancerManagement of low-risk prostate cancerOlder patientsProstate cancer-specific mortality ratesConservative managementProstate cancer-specific mortalityCancer-specific mortality ratesActive surveillance/watchful waitingRate of conservative managementOlder menCancer-specific mortalityShort-term safetyQuality-of-life implicationsDefinitive treatmentYounger patientsOverall mortalityPatientsMortality rateProstateNational databaseCancer
2017
Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST)
Patrice G, Lester-Coll N, Yu J, Amdahl J, Delea T, Patrice S. Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST). International Journal Of Radiation Oncology • Biology • Physics 2017, 100: 97-106. PMID: 29029885, DOI: 10.1016/j.ijrobp.2017.08.041.Peer-Reviewed Original ResearchConceptsExtensive-stage small cell lung cancerThoracic radiation therapyProgression-free survivalIncremental cost-effectiveness ratioExtensive-stage small cell lung cancer patientsSmall cell lung cancerCell lung cancerStandard treatmentLung cancer trialsRadiation therapyOverall survivalLung cancerUS health care payer perspectiveLong-term survival benefitCancer trialsFavorable incremental cost-effectiveness ratiosProgressive metastatic diseaseHealth care payer perspectiveProportion of patientsBase-case analysisFollow-up intervalCost-effectiveness ratioMetastatic diseasePostprogression survivalPayer perspective